Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody|cas:905703-97-1|西域试剂

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody,95.0%

产品编号：Bellancom-P99294| CAS NO：905703-97-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99294		￥4000.00	杭州北京（现货）
Bellancom-P99294		￥10400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody

产品介绍

Ganitumab (AMG 479) 是一种重组人1型胰岛素样生长因子受体 (IGF1R) 单克隆抗体。Ganitumab 识别具有亚纳米摩尔亲和力的小鼠 IGF1R (K_D=0.22 nM)，并抑制小鼠 IGF1R 与 IGF1 和 IGF2 的相互作用。Ganitumab 可用于癌症研究。

生物活性

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.

体外研究

Ganitumab (AMG 479; 0.032-500 nM; 10 分钟; CT26 细胞) 结合 mIGF1R 并抑制 IGF1 和 IGF2 介导的 mIGF1R 的激活。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	CT26 cells
Concentration:	0.032-500 nM
Incubation Time:	10 minutes
Result:	Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner.

体内研究
(In Vivo)

Ganitumab (AMG 479; 1 mg/剂; i.p; Naïve 和荷瘤小鼠) 抑制 IGF1 诱导的小鼠肺中 mIGF1R 的激活。
Ganitumab (300 μg/剂; i.p.; 雌性无胸腺裸鼠) 减少外周血中性粒细胞。
Ganitumab (300 μg/剂; i.p.;雄性无胸腺裸鼠) 导致雄性小鼠糖耐量受损，并增加血清中 mGH，mIGF1 和 mIGFBP3。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naïve and tumor-bearing mice
Dosage:	1 mg/dose
Administration:	Intraperitoneal injection
Result:	Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.

Animal Model:	Male athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Had significantly higher serum glucose levels than hIgG1-pretreated mice. Increased serum levels of mIGF1, mIGFPB3 and mGH.

Animal Model:	Female athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naïve and tumor-bearing mice
Dosage:	1 mg/dose
Administration:	Intraperitoneal injection
Result:	Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.

Animal Model:	Male athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Had significantly higher serum glucose levels than hIgG1-pretreated mice. Increased serum levels of mIGF1, mIGFPB3 and mGH.

Animal Model:	Female athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naïve and tumor-bearing mice
Dosage:	1 mg/dose
Administration:	Intraperitoneal injection
Result:	Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.

Animal Model:	Male athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Had significantly higher serum glucose levels than hIgG1-pretreated mice. Increased serum levels of mIGF1, mIGFPB3 and mGH.

Animal Model:	Female athymic nude mice
Dosage:	300 μg/dose
Administration:	Intraperitoneal injection, twice per week for a total of five doses
Result:	Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.